Neurocrine Biosciences Inc., a biopharma company in San Diego, announced that it has appointed Dr. Alfred W. Sandrock Jr. to its board of directors.

Sandrock is the current group senior vice president and chief medical officer of Biogen Inc., a global, multibillion dollar biotech based in Cambridge, Mass.

"We are fortunate to have a person of Al's caliber join our board of directors,” said William H. Rastetter, chairman of the board of Neurocrine Biosciences. “Dr. Sandrock brings a distinguished track record of success in the development, approval and commercialization of many significant neurological products including Tysabri and Tecfidera. His knowledge and expertise will be a valuable resource for Neurocrine's continued transition into a commercial organization."

Since joining Biogen in 1998, Sandrock has held several senior executive positions, including senior vice president of development sciences, senior vice president of neurology research and development, and vice president of clinical development, neurology.

During his tenure at Biogen, Sandrock has been responsible for the clinical development and approval of Tysabri, Plegridy, Tecfidera, Alprolix, and Eloctate.